ProteKt secures funding for PKR kinase inhibitor-based therapies

Israeli biotech company ProteKt Therapeutics, which is focused on developing new PKR kinase inhibitor-based therapies for Alzheimer's Disease and other neurodegenerative diseases, has secured $3.6 ... Read More